As part of the study, third party researchers analysed the patterns of carbohydrates that attach to the KLH protein through a biologic process known as glycosylation.
The compositional profile of these glycans are believed to enhance the immunogenicity of KLH.
Due in part to the large size and complexity of this glycosylation, KLH has never been synthesized.
To produce KLH, hemocyanin protein is extracted from its native source using Stellar's patented process and then purified and manufactured into various grades and formulations.
Stellar executive vice president of corporate development, Gregory T. Baxter, PhD reported that study results demonstrated highly consistent molecular structure from batch to batch, a key attribute for a biologically sourced protein, and that the greater insight into the characteristics of the KLH molecule revealed in the study may be useful in better understanding conjugation efficiency, a metric important to therapeutic vaccine developers.
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Micron Biomedical names new scientific advisor to CEO
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences